Pharmacogenetics in Colorectal Cancer
Author:
Ferraldeschi Roberta
Publisher
Springer Netherlands
Reference202 articles.
1. Allan JM, Wild CP, Rollinson S et al (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 98:11592–11597
2. Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. J Clin Oncol 27:2091–2096
3. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
4. Amstutz U, Farese S, Aebi S, Largiadèr CR (2008) Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 27:54
5. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921–6926